Close menu




March 1st, 2023 | 14:01 CET

BioNTech, BioNxt Solutions, Bayer - Turn of the tide

  • Biotechnology
  • Covid19
Photo credits: pixabay.com

Just how fundamental biotechnology already is for humanity was demonstrated by the development of the various COVID vaccines, which was extremely rapid by historical standards. Previously unknown companies such as BioNTech, Valneva and CureVac came into the focus of the stock market and were able to multiply within a very short time. Even after the pandemic has ended, research in the biotech sector is running at full speed. This is giving rise to new, innovative growth companies that could follow a similar trajectory in the future.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , Bionxt Solutions Inc. | CA0909741062 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNxt Solutions - Broadly diversified

    One of these promising companies is the broadly diversified life sciences accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and the manufacture and evaluation of new active pharmaceutical ingredients. The Company, which has a market capitalization of EUR 36.88 million, conducts research and development activities in North America and Europe, with an operational focus in Germany.

    Within the three business areas, significant successes have been celebrated in the recent past, with several projects about to enter commercialization. In the area of psilocybin research, the Canadians were able to file a patent application for their collection of novel psychedelic substances that can be targeted for the treatment of neuropsychiatric, neurodegenerative and neuroinflammatory disorders. These include depression, tobacco, opiate and cocaine addiction, and alcoholism. Globally, around 350 million people suffer from depression. This figure alone gives an idea of the enormous potential.

    At the end of October, BioNxt reported positive in vivo results of a rotigotine patch for treating Parkinson's disease. Rotigotine is an active ingredient already approved in Europe and the US for the treatment of Parkinson's disease and restless legs syndrome. XPhyto compared an active ingredient patch currently on the market with the patch developed by its German subsidiary Vektor Pharma TF GmbH. Here, the results for the criteria "penetration of the skin" and "dissolution behaviour of the active ingredient" clearly exceeded the predictions. With the results available, the Company is now preparing for a pilot clinical study in humans, which is to be completed in the second quarter of 2023.

    In parallel, BioNxt plans to build up appropriate capacity for commercial manufacturing at its German drug development facility. The clearest advantage of adding rotigotine via patches rather than oral administration is the improved efficacy of the dopamine agonist. As a patch, the bioavailability of the active ingredient can be increased to 24h with a simultaneous slow and steady release of rotigotine into the body. The market volume in Parkinson's disease has been estimated at USD 518 million for 2021, according to market research institute Wissen Market Research.

    Bayer - Outlook below expectations

    Fiscal 2022 ended with strong sales growth in the double-digit percentage range for the pharmaceutical and agricultural giant from Leverkusen. The main driver was the agricultural division and high prices for the controversial crop protection agent glyphosate. According to the report, Group sales grew by 15% to EUR 50.7 billion, while the operating result grew by more than 20% to EUR 13.5 billion. Net income even increased fourfold to EUR 4.15 billion. Due to the strong earnings growth, a dividend of EUR 2.40 per share was announced, an increase of EUR 0.40 compared to the previous year.

    However, Bayer expects growth to slow in the current fiscal year. The reasons for this are, on the one hand, falling prices for the weed killer glyphosate and higher costs and price pressure for some medicines. Accordingly, the DAX-listed group is calculating sales of between EUR 51 billion and EUR 52 billion. Adjusted operating profit Ebitda is expected to reach EUR 12.5 to 13 billion on this basis. Free cash flow is expected to be EUR 3 billion, just below the EUR 3.1 billion achieved in 2022.

    The analysts at Deutsche Bank Research continue to be positive, maintaining their "buy" rating on Bayer shares with a price target of EUR 79 following the announcement of the figures. The Company's fourth-quarter sales were in line with expectations, while adjusted operating profit was slightly higher than expected. The outlook for sales for the current fiscal year was also in line with forecasts, while the estimates for earnings per share had to be adjusted downwards.

    BioNTech - Critical mark

    Corona is disappearing increasingly from our society, and the willingness to vaccinate is drastically decreasing, as well as the share prices of vaccine manufacturers. The share of the German flagship BioNTech lost about a quarter of its stock market value since the beginning of the year and is trading at EUR 130.27, close to the high from 2020. If this support is broken, the next short-term target will be EUR 117.

    Together with US partner Pfizer, the Mainz-based company has submitted an application to the US Food and Drug Administration (FDA) for full approval of its Omicron-adapted COVID-19 vaccine. The companies are seeking approval for the updated vaccine as both a primary and booster vaccine for individuals 12 years of age and older. FDA advisors had voted unanimously in January to use the same coronavirus strain for both the primary and booster doses of the COVID-19 vaccine to simplify the vaccination schedule in the United States.

    If the request is approved, individuals will be able to receive the updated vaccine as the first dose, rather than using the original vaccine for the first doses, before having access to the updated version for the booster shots, the Company said.


    The Corona pandemic continues to ebb, and a final easing should begin no later than spring, which is likely to weigh heavily on vaccine maker BioNTech's sales figures. Bayer disappointed with its outlook for 2023, while BioNxt reported positive developments in all business areas.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read

    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

    Read